

Medan, 28 June 2023

To:

Editor-in-Chief of Journal of Biomedicine and Translation Research
in Semarang, Indonesia

Dear Professor,

We wish to submit a case report entitled “**Case Report: Recalcitrant Incomplete Secukinumab Administration in a Psoriasis Patient**” for consideration by Biomedicine.

We confirm that this work is original and that the manuscript has not been published elsewhere, nor is it currently under consideration for publication elsewhere. We also confirm that there is no falsification or fabrication of data and no plagiat content in the article.

We believe this manuscript is appropriate for publication by Biomedicine because adherence and persistence to biological agents for psoriasis diseases are still challenging. One of these biological agents is Secukinumab, a fully human IgG1k anti-interleukin-17A monoclonal antibody widely used. However, a limited number of studies report the effect of low adherence and persistence to Secukinumab. Due to this reason, it becomes the novelty of this case report to reveal the impact of recalcitrant Secukinumab administration on psoriasis treatment. All authors of this manuscript have approved the final version of this submitted manuscript.

We have no conflicts of interest to disclose.

Thank you for your consideration of this manuscript.

Sincerely,



[Joice Sonya Gani Panjaitan]



[Suhartomi]